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Reference values for white blood-
cell-based inflammatory markers in 
the Rotterdam Study: a population-
based prospective cohort study
Jesse Fest  1,2, Rikje Ruiter2, M. Arfan Ikram  2, Trudy Voortman  2, Casper H. J. van Eijck1 & 
Bruno H. Stricker2
Novel prognostic inflammatory markers of cancer survival and cardiovascular disease are; the 
neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic 
immune-inflammation index (SII). As normal values for these markers are unknown, our objective 
was to obtain reference values in the general population. We obtained data from a population-based 
prospective cohort study of individuals aged 45 years and over between 2002 and 2014. Absolute 
blood counts were used to calculate the NLR, PLR and SII. All inflammatory indices followed a log-
normal distribution. We calculated the mean and 95% reference intervals in an unselected population. 
Furthermore we studied whether the inflammatory markers differed between age categories and 
gender. In total 8,711 participants (57.1% female; mean age 65.9 years, standard deviation 10.5 years) 
were included. Mean values and corresponding 95% reference intervals for the NLR were: 1.76 (0.83–
3.92), for PLR: 120 (61–239) and for SII: 459 (189–1168). The inflammatory markers increased with age. 
The PLR and SII were higher in females, whilst the NLR was higher in males. In conclusion, we provided 
reference values for new inflammatory markers. All increase with age and vary with gender. This 
provides context that allows for proper interpretation of their potential value in future clinical practice 
and research.
Low-grade inflammation is associated with important chronic diseases in the elderly such as diabetes, cardiovas-
cular disease and cancer1–7. For instance, several immune mechanisms play a role in the formation and activation 
of atherosclerotic plaques that lead up to cardiovascular disease and the over-expression of TNF-α is associated 
with insulin resistance and subsequently type 2 diabetes2,7. Furthermore chronic inflammation is also since long 
considered as one of the basic pathogenic processes in cancer development3,4. Additionally, it is thought that, once 
the cancer has developed, the immune system plays an important role in surveillance and elimination of cancer 
cells4.
This has led to the examination of various inflammatory markers and indices as a potential biomarker or 
prognostic factors8. Traditional measures, such as C-reactive protein (CRP) and the erythrocyte sedimentation 
rate (ESR) have been extensively studied, previously5,6,8. Recently, several new white blood-cell-based inflam-
matory indices have been introduced as prognostic markers: the neutrophil-to-lymphocyte ratio (NLR), the 
platelet-to-lymphocyte ratio (PLR) and the systemic immune inflammation index (SII)9–13.
Both the NLR and PLR are ratios; of the peripheral neutrophil and lymphocyte counts and the peripheral 
platelet and lymphocyte counts, respectively. The SII has integrated peripheral lymphocyte, neutrophil and plate-
let counts into one indicator, with the aim to better reflect the balance between the host’s inflammatory and 
immune status10. The NLR, PLR and SII can be easily calculated from low-cost and frequently used available 
measures and are thought to be more specific than CRP or the ESR.
It is generally assumed that the levels of these inflammatory markers are elevated in individuals with cardi-
ovascular disease or cancer. However, normal ranges for the NLR, PLR or SII are unknown and most research-
ers have estimated cut-off points within their sample population, resulting in a wide and inconsistent range of 
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cut-off points used in current literature12–14. Reference values are therefore needed to put the results of previous 
studies into a context that allows for proper interpretation of their potential clinical value. The objective of this 
study was therefore, to obtain these reference values from the general population in a large and longstanding 
population-based prospective cohort study.
Methods
Study setting. The analyses were performed in the Rotterdam Study, a long term population based prospec-
tive cohort study in the Rotterdam area, the Netherlands. Its rationale and design have been described extensively, 
previously15,16. Briefly, inhabitants of the suburb Ommoord, aged 55 years and older, were invited to participate 
in 1989. Of the 10,275 invited subjects, 7,983 entered the study (78%). A second cohort of 3,011 persons (67% 
response), was enrolled between 2000 and 2001. In 2006 a third cohort, with 3,932 persons of 45 years and older, 
was enrolled (65% response). This resulted in an overall study population of 14,926 individuals, aged 45 years 
and older.
Participants were visited at home at baseline for a standardized interview on health status. Subsequently, a 
physical examination followed during a visit at the study centre. These interviews and visits were repeated approx-
imately every four years (Supplementary Figure 115). The Rotterdam Study has been approved by the institu-
tional review board (Medical Ethics Committee) of the Erasmus Medical Center and by the review board of The 
Netherlands Ministry of Health, Welfare and Sports. Informed consent was obtained from all participants. All 
methods were performed in accordance with the relevant guidelines and regulations.
Definition of study population. White blood cell count, including leucocyte differentials, were only part 
of the protocol from the fourth visit of the first cohort onwards (Supplementary Figure 115). Therefore, for this 
study we used information from the fourth centre visit of the first cohort (RS-I-4 (January 2002–July 2004); 
n = 3,550), the second visit of the second cohort (RS-II-2 (July 2004–December 2005); n = 2,468) and the baseline 
visit of the third cohort (RS-III-1 (February 2006–December 2008); n = 3,932) and onwards. Of the 9,950 eligible 
participants; 8,912 (89.6%) donated blood. Participants for whom the NLR, PLR or SII could not be calculated, 
due to missing values (n = 201), were excluded. This resulted in a study cohort of 8,711 individuals (Fig. 1).
Collection of the samples. Fasting blood samples were collected at the study centre and were stored at 
−80 °C until full blood count measurements. These measurements included absolute counts of granulocytes, lym-
phocytes and platelets and were performed using the COULTER® Ac·T diff2™ Hematology Analyzer (Beckman 
Coulter, San Diego, California, USA). In an additional analysis, the normal distribution of hemoglobin and CRP 
levels were assessed as well. CRP levels were measured using a particle enhanced immunoturbidimetric assay 
(Roche Diagnostics, Mannheim, Germany).
The neutrophil-to-lymphocyte ratio was calculated on the basis of absolute peripheral granulocyte (as a 
proxy for the neutrophil count) (N; ×109/Liter) and lymphocyte (L; ×109/Liter) blood counts, using the formula: 
NLR = N/L9.
Figure 1. Flowchart of the study population.
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The platelet-to-lymphocyte ratio was calculated on the basis of peripheral platelet(P; ×109/Liter) and lympho-
cyte (L; ×109/Liter) blood counts, using the formula: PLR = P/L12.
The systemic immune-inflammation index (SII) was calculated on the basis of peripheral platelet (P; ×109/
Liter), granulocyte (N; ×109/Liter) and lymphocyte (L; ×109/Liter) blood counts, using the following formula: 
SII = P * N/L10. All the inflammatory markers are either ratios or indices and as such do not have a unit.
Assessment of other variables. The following individual characteristics were determined at study entry 
interview or during the visits at the study centre: age, sex, study entry body mass index (BMI; kg/m²), smoking 
status (never/former/current), and socio-economic status, based on education level (SES; high [university/higher 
vocational education]/intermediate [general secondary education/intermediate vocational education]/low [lower 
secondary education/primary education with a higher, but not completed education/primary education]). Status 
on type 2 diabetes was ascertained either at study entry or during follow-up by use of general practitioners’ 
records (including laboratory glucose measurements), hospital discharge letters, and serum glucose measure-
ments from the centre visits17. Diabetes was defined, in concordance with the WHO guidelines, as a fasting glu-
cose ≥7.0 mmol/Liter or use of glucose – lowering medication18.
Statistical Analyses. The distribution of the data was visualized by means of histograms and Q-Q 
plots. Since none of the inflammatory markers were normally distributed and all were slightly skewed to 
the right (Fig. 2), we log-transformed them prior to performing any of the analyses. These values were then 
back-transformed to provide reference values for clinical practice19. To present reference values of the inflam-
matory markers we calculated the 2.5% and 97.5% reference limits in our study population. The 2.5% and 97.5% 
Figure 2. Distributions of the inflammatory markers in the general population. Panel A. NLR Panel B. PLR 
Panel C. SII.
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reference limits reflect the 2.5th and 97.5th percentiles, respectively. Subsequently, the differences between the 
distribution of the inflammatory markers in females versus males and different age classes [45–54; 55–64; 65–74; 
75–84; ≥85 years], were assessed using the Student’s t-test or ANOVA.
To evaluate whether inflammatory markers indeed truly change with age we used a second measurement in 
the same individual, which was on average 6.1 years later (range 3.0–10.9 years), from the blood draw at RS-I-5 
(March 2009–January 2011); n = 2,147; RS-II-3 (February 2011–February 2012); n = 1,893 and RS-IIII-2 (March 
2012–June 2014); n = 3,122, respectively (see Supplementary Figure 1). Out of the 7,162 living participants, in 
total 5,849 participants had two measurements available. Differences were assessed using a Paired Samples t-test.
To see whether the distribution was influenced by any current infection, we further assessed the associations 
in individuals for whom a CRP (mg/Liter) measurement was available (RSIII-1: 3,462). We considered all indi-
viduals with a clinically elevated CRP level (CRP>10 mg/Liter) as having a potential infection and excluded them 
from the analysis.
All analyses were performed using SPSS software (Version 21.0). Statistical significance of associations was 
accepted at a P-value < 0.05.
Data availability. Data can be obtained upon request. Requests should be directed towards the management 
team of the Rotterdam Study (secretariat.epi@erasmusmc.nl), which has a protocol for approving data requests. 
Because of restrictions based on privacy regulations and informed consent of the participants, data cannot be 
made freely available in a public repository.
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the 
Ministry of Health, Welfare and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO 
(Population Studies Act: Rotterdam Study)”. All participants provided written informed consent to participate in 
the study and to obtain information from their treating physicians.
Results
Main analysis. In total 8,711 participants were included in the analyses for the three inflammatory measures 
(see Supplementary Figure 1). The cohort characteristics are presented in Table 1.
The mean NLR in the general population was, 1.76, with a 2.5% limit at 0.83 and 97.5% limit at 3.92. The mean 
NLR was statistically significantly higher in males (mean of 1.88) than in females (mean of 1.68), P-value < 0.001 
(see Supplementary Figure 2). The mean NLR was generally higher in the higher age categories, with the highest 
age category >85 years of age having a mean NLR of 2.13 versus those in the youngest age category of 45–54 
years of age of 1.63 (P-value < 0.001, Table 2). The shape of distribution of the NLR also changed with age, being 
almost normal for the younger age categories whilst becoming more asymmetrical with age (see Supplementary 
Figure 3). The Skewness statistic and standard error (SE) are: 1.4 (SE: 0.06), 2.2 (SE: 0.05), 2.6 (SE: 0.05), 2.0 (SE: 






Sex Male 3,733 42.9
Female 4,978 57.1
Age (years) Mean (SD) 65.9 10.5





SES High 1,651 19.2
Intermediate 3,597 41.9
Low 3,346 38.9
BMI (kg/m²) Mean (SD) 27.1 4.1
Smoking Current 1,734 20.2
Former 4,288 49.9
Never 2,570 29.9
Diabetes Status 952 10.9
Table 1. Cohort characteristics. SD; standard deviation, SES; socio-economic status, BMI; Body Mass Index. 
Unknown: SES (117), smoking (119) and BMI (167). Sex, SES status and BMI at baseline. Age, smoking status 
and DM status at time of blood draw. To assess differences between distribution of the inflammatory markers 
amongst the various covariates we used the Students’ t-test or ANOVA (Analysis of Variance). All tests were 
statistically significant.
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Similar to the NLR, both the PLR and SII were higher in the higher age categories (P-value < 0.001 for both). 
However the PLR and SII were higher in women than in men (P-value < 0.001 and 0.027, respectively) (see 
Table 2, Supplementary Figures 2 and 3). These results were consistent within the three sub-cohorts separately 
(data not shown).
To evaluate whether inflammatory markers indeed increase over time, we assessed the change of the inflam-
matory markers in 5,842 participants with two measurements. At the second blood draw the mean NLR was 1.90 
and the mean SII was 465, both significantly higher (Paired Samples t-test: P-value < 0.001 for both). The mean 
PLR at the second blood draw was 119 and significantly lower compared to the first blood draw. The median 
within-person change was for the NLR: 0.10 (IQR: −0.21–0.44), for the PLR: −3 (−20–14) and for the SII: 19 
(−72–126).
Sensitivity analyses. To see whether the distribution was influenced by any current infection, we investi-
gated the effect of excluding individuals with an elevated CRP level. CRP measurements were only performed for 
3,462 individuals in RS-III-1, of whom in 133 individuals (3.8%) the CRP level was >10 mg/L and 3,322 (96.0%) 
individuals had a normal CRP level. Individuals with an elevated CRP level had a significantly higher mean NLR 
(2.24), PLR (129) and SII (691) compared to those with a normal CRP level; mean NLR (1.61), PLR (117) and SII 
(444) (Student’s t-test: P-value for all <0.001). However, removing individuals with an elevated CRP from the pop-
ulation did not affect the mean of the overall population for any of the inflammatory indices. It also only slightly 
affected the 97.5% limit. When individuals with a clinically elevated CRP were excluded from the population; the 
97.5% limit changed from 3.60 to 3.50 (for the NLR), from 225 to 221 (for the PLR) and from 1112 to 1061 (for the 
SII), respectively. Individuals with an elevated CRP at the first measurement showed a decrease in the NLR levels 
(median −15.5%), whereas for individuals with a normal CRP, the median NLR increased with 6.3%.
Discussion
In the past few years, novel inflammatory markers for prognosis in patients with cancer and cardiovascular dis-
ease have been described in the literature. The NLR, PLR and the SII are all composites of blood cell counts, which 
are standard, low-cost measurements that are already incorporated into daily clinical practice and can be calcu-
lated easily from these widely available current measures.
However, the reference limits of these white blood –cell based inflammatory markers in the general popula-
tion are unknown. Therefore the cut-off values, used for risk assessment, were generally estimated in a clinical 
sample population consisting of patients with solid tumors. This has resulted in a wide and inconsistent range of 
cut-off points presented throughout the present literature. To properly evaluate the clinical significance of these 
NLR PLR SII
General Population mean 1.76 120 459
2.5% limit 0.83 61 189
97.5% limit 3.92 239 1168
Sex Male mean 1.88 112 453
2.5% limit 0.88 57 185
97.5% limit 4.14 230 1168
Female mean 1.68 126 463
2.5% limit 0.80 65 194
97.5% limit 3.80 246 1169
Age category (years) 45–54 mean 1.63 118 456
2.5% limit 0.80 62 189
97.5% limit 3.44 211 1063
55–64 mean 1.61 116 436
2.5% limit 0.79 60 186
97.5% limit 3.53 226 1109
65–74 mean 1.82 119 455
2.5% limit 0.86 60 186
97.5% limit 3.92 239 1131
75–84 mean 2.02 127 500
2.5% limit 0.96 61 196
97.5% limit 4.53 268 1373
≥85 mean 2.13 131 522
2.5% limit 0.89 63 205
97.5% limit 5.86 282 1798
Table 2. Reference values for the inflammatory markers. NLR = neutrophil-to-lymphocyte ratio = absolute 
peripheral granulocyte count (×109/L)/absolute lymphocyte count (×109/L). PLR = platelet-to-lymphocyte 
ratio = absolute peripheral platelets count (×109/L)/absolute peripheral lymphocyte count (×109/L). 
SII = systemic immune-inflammation index = absolute peripheral granulocyte count (×109/L)/absolute 
lymphocyte count (×109/L). *absolute peripheral platelets count (×109/L).
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new inflammatory markers we need to be able to interpret them in the context of the normal ranges. Knowledge 
of their distribution and reference values within the general population is therefore essential. This paper provides 
those reference values, obtained from a large population-based cohort aged 45 years and older.
All inflammatory markers had a skewed (right) distribution. Even when outliers with a clinically elevated 
CRP were excluded from the population, the distribution in the general population remained asymmetrical. The 
distributions also did not change when stratified for sex.
However, the distribution of the SII, NLR and PLR was different between age categories (see Supplementary 
Figure 3). This is especially apparent for the distribution of the NLR. The skewed distribution of inflammatory 
markers in the overall population can largely be attributed to the distribution amongst the higher age categories, 
whereas the distribution of the NLR amongst the lower age categories is almost normal. We showed that all 
inflammatory markers increased with age. This resembles the distribution of CRP and the ESR over different age 
categories20,21. Possibly the distribution skews with age, however it is also possible, and perhaps more likely, that 
its non-symmetry can be attributed to diseases that become more prevalent with age, such as diabetes, cardiovas-
cular disease and cancer. Future research should elucidate the relationship between these inflammatory markers 
and morbidity in the general population.
Strengths of this study are its prospective nature, its size, and the fact that it is population based. Therefore, we 
obtained a good estimate of the true normal range of the inflammatory markers within the general population 
aged 45 years and older and additionally provided insight into the variation of these inflammatory markers. We 
showed that they increase with age (consistent for all three sub-cohorts) and that the reference values are different 
for men and women, which is consistent with current literature on CRP and ESR20,21. Furthermore, for the NLR 
and SII we showed that they increase over time.
However, there are some limitations of this study that deserve mentioning. To be able to calculate the inflam-
matory markers, we needed a differential white blood count. For the absolute neutrophil count we had to 
take the total granulocyte count as a proxy. However, any misclassification of granulocytes would probably be 
non-differential and therefore would not have introduced any bias into the results. Another potential limitation is 
that this measurement was only part of the protocol from the fourth study centre visit of the first cohort onwards, 
meaning that we have no information on the one-third of the population that had died before that time point. 
Some participants refused to give blood, meaning that in total about 40% of the original population had to be 
excluded from this analysis. However, we do not believe that the exclusion of this part of the study population has 
introduced any bias into this study, as this reflects what happens in the general population.
Although the CRP measurements are available for only a part of the population, a sufficient number remains 
to draw conclusions on the effect of an elevated CRP level on the inflammatory markers.
Lastly the population we examined consisted predominantly of Caucasians (98%) and raises the question 
whether these results are generalizable towards other ethnic groups. It is known that there are hematologic dif-
ferences between, for instance, Caucasians and African-Americans22–24. Although our results could be used as a 
bench-mark, we would suggest similar studies amongst different ethnicities to further confirm these new refer-
ence values.
In conclusion, this paper provides reference values for three novel prognostic systemic inflammatory markers; 
the neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio and the systemic immune-inflammation. 
This is essential to further evaluate the potential value for clinical practice of these new inflammatory markers.
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